Experienced in Primary Familial Brain Calcification

Dr. Rajesh B. Pahwa

The University of Kansas Hospital
Kansas University Physicians Inc
Kansas City, KS
Experienced
in Primary Familial Brain Calcification
Specialties:Neurology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Rajesh Pahwa is a Neurologist in Kansas City, Kansas. Dr. Pahwa and is rated as an Experienced provider by MediFind in the treatment of Primary Familial Brain Calcification. His top areas of expertise are Parkinson's Disease, Essential Tremor, Drug Induced Dyskinesia, Deep Brain Stimulation, and Thalamotomy. Dr. Pahwa is currently accepting new patients.

His clinical research consists of co-authoring 160 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in KS
Hospital Affiliations
Adventhealth Shawnee Mission
University Of Kansas Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Oscar
  •  Humana

Locations

KANSAS UNIVERSITY PHYSICIANS INC
3599 Rainbow Blvd, Kansas City, KS 66103
913-588-1227
Other Locations
KANSAS UNIVERSITY PHYSICIANS INC
3901 Rainbow Blvd, Suite 5300, Kansas City, KS 66160
913-588-6210
KANSAS UNIVERSITY PHYSICIANS INC
4000 Cambridge St, Kansas City, KS 66160
913-588-1227

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 1 Clinical Trial, Evaluating the Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 1 Clinical Trial, Evaluating the Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Biological, Other
Study Drug: VY-AADC02
Study Phase: Phase 1
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: CVN424
Study Phase: Phase 2
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
Parkinson's Foundation: PD Generation: Mapping the Future of Parkinson's Disease
Parkinson's Foundation: PD Generation: Mapping the Future of Parkinson's Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Drug: Neflamapimod
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
Enrollment Status: Terminated
Publish Date: February 28, 2022
Intervention Type: Drug
Study Drug: BIIB054
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
Enrollment Status: Completed
Publish Date: November 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Enrollment Status: Completed
Publish Date: December 01, 2020
Intervention Type: Drug
Study Phase: Phase 2
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
Enrollment Status: Completed
Publish Date: January 09, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Enrollment Status: Completed
Publish Date: April 19, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

159 Total Publications

Updates in essential tremor.
Updates in essential tremor.
Journal: Parkinsonism & related disorders
Published: February 29, 2024
Similar Doctors
Expertise in
63
conditions
Dr. Richard M. Dubinsky
Neurology
Expertise in
63
conditions
Dr. Richard M. Dubinsky
Neurology

Kansas University Physicians Inc

4000 Cambridge St, 
Kansas City, KS 
 (0.4 mi)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Dubinsky is a Neurologist in Kansas City, Kansas. Dr. Dubinsky and is rated as a Distinguished provider by MediFind in the treatment of Primary Familial Brain Calcification. His top areas of expertise are Huntington Disease, Drug Induced Dyskinesia, Tourette Syndrome, and Tardive Dyskinesia. Dr. Dubinsky is currently accepting new patients.

Expertise in
33
conditions
Dr. James L. Southwell
Neurology
Expertise in
33
conditions
Dr. James L. Southwell
Neurology

Kansas University Physicians Inc

4000 Cambridge St, 
Kansas City, KS 
 (0.4 mi)
913-588-1227
Languages Spoken:
English, Hungarian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

James Southwell is a Neurologist in Kansas City, Kansas. Dr. Southwell and is rated as an Advanced provider by MediFind in the treatment of Primary Familial Brain Calcification. His top areas of expertise are Migraine, Neuralgia, Headache, and Congenital Insensitivity to Pain with Anhidrosis. Dr. Southwell is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile